Budesonide and formoterol in a single inhaler controls asthma in adolescents

International Journal of Adolescent Medicine and Health

Volumn 16, Issue 2, 2004, Pages 91-105

  Pohunek, Petr ^a,b,c   Tal, Asher ^a,b  

^a CHARLES UNIVERSITY   (Czech Republic)

^b BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^c UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

Author keywords

Adherence; Adolescents; Asthma; Budesonide; Compliance; Formoterol; Symbicort

Indexed keywords

ANTIASTHMATIC AGENT; ANTIINFLAMMATORY AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; BUDESONIDE; BUDESONIDE PLUS FORMOTEROL; CORTICOSTEROID; CROMOGLYCATE DISODIUM; FLUTICASONE PROPIONATE; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LONG ACTING DRUG; MONTELUKAST; NEDOCROMIL SODIUM; PLACEBO; PREDNISOLONE; SALBUTAMOL; SHORT ACTING DRUG; STEROID; TERBUTALINE; THEOPHYLLINE; ZAFIRLUKAST;

ADD ON THERAPY; ADOLESCENT; ADRENAL DISEASE; ASTHMA; BRONCHITIS; BRONCHODILATING ACTIVITY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COUGHING; DISEASE CONTROL; DISEASE EXACERBATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE REGIMEN; GROWTH DISORDER; HEADACHE; HUMAN; HYPOPHYSIS DISEASE; HYPOTHALAMUS DISEASE; INHALER; MORBIDITY; PATIENT COMPLIANCE; PHARYNGITIS; PRESCRIPTION; RESPIRATORY TRACT INFECTION; REVIEW; RHINITIS; RISK FACTOR; SELF CARE; SYMPTOMATOLOGY; TREMOR; VIRUS INFECTION; VOMITING;

EID: 3242666027     PISSN: 03340139     EISSN: None     Source Type: Journal    
DOI: 10.1515/IJAMH.2004.16.2.91     Document Type: Review

References (67)

1. Sears MR. Descriptive epidemiology of asthma. Lancet 1997;350(Suppl. 2):SII1-SII4.
2. National Institutes of Health: National Heart, Lung, and Blood Institute. Global initiative for asthma. Global strategy for asthma management and prevention. Bethesda, MD: National Institutes of Health (publication No. 02-3659); 2002.
3. Mannino DM, Homa DM, Pertowski CA, Ashizawa A, Nixon LL, Johnson CA, et al. Surveillance for asthma - United States, 1960-1995. MMWR CDC Surveill Summ 1998;47(1):1-27.
4. Price J, Kemp J. The problems of treating adolescent asthma: what are the alternatives to inhaled therapy? Respir Med 1999;93(10):677-84.
5. British Thoracic Society. British Guideline on the Management of Asthma. Thorax 2003;58(Suppl. 1):il-i94.
6. Halterman JS, Aligne CA, McBride JT, Szilaghi PG. Inadequate therapy for asthma among children in the United States. Pediatrics 2000;105(1 Pt 3):272-6.
7. Price JF. Issues in adolescent asthma: what are the needs? Thorax 1996;51 (Suppl. 1):S13-S17.
8. Barnes PJ, Pedersen S, Busse WW. Efficacy and safety of inhaled corticosteroids. New developments. Am J Respir Crit Care Med 1998;157 (3 Pt 2):S1-S53.
9. Greening AP, Ind PW, Northfield M, Shaw G. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Lancet 1994;344 (8197):219-24.
10. Pauwels RA, Löfdahl C-G, Postma DS, Tattersfield AE, O'Byrne P, Barnes PJ, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. N Engl J Med 1997;337(20):1405-11.
11. O'Byrne PM, Barnes PJ, Rodriguez-Roison R, Runnerstrom E, Sandstrom T, Svensson K, et al. Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. Am J Respir Crit Care Med 2001;164(8 Pt 1):1392-7.
12. Akpinarli A, Tuncer A, Saraclar Y, Sekerel BE, Kalayci O. Effect of formoterol on clinical parameters and lung functions in patients with bronchial asthma: a randomised controlled trial. Arch Dis Child 1999;81(1):45-8.
13. von Berg A, Papageorgiou Saxoni F, Wille S, Carrillo T, Kattamis C, Helms P. 3-month treatment with formoterol Turbuhaler in children with asthma. Eur Respir J 1998; 12(Suppl. 28):S36.
14. Agertoft L, Pedersen S. Effects of long-term treatment with an inhaled corticosteroid on growth and pulmonary function in asthmatic children. Respir Med 1994;88(5):373-81.
15. Verini M, Rossi N, Dalfino T, Verrotti A, Di Gioacchino M, Chiarelli F. Lack of correlation between clinical patterns of asthma and airway obstruction. Allergy Asthma Proc 2001;22(5):297-302.
16. Jónasson G, Carlsen K-H, Mowinckel P. Asthma drug adherence in a long term clinical trial. Arch Dis Child 2000; 83(4):330-3.
17. Milgrom H, Bender B, Ackerson L, Bowry P, Smith B, Rand C. Non-compliance and treatment failure in children with asthma. J Allergy Clin Immunol 1996;98(6 Pt 1): 1051-7.
18. Jatulis DE, Meng Y-Y, Elashoff RM, Schocket AL, Evans R-M, Hasan AG, et al. Preventive pharmacologic therapy among asthmatics: five years after publication of guidelines. Ann Allergy Asthma Immunol 1998;81(1): 82-8.
19. van der Palen J, Klein JJ, van Herwaarden CLA, Zielhuis GA,Seydel ER. Multiple inhalers confuse asthma patients. Eur Respir J 1999; 14(5):1034-7.
20. Buston KM, Wood SF. Non-compliance amongst adolescents with asthma: listening to what they tell us about self-management. Fam Pract 2000;17(2): 134-8.
21. Cohen R, Franco K, Motlow F, Reznik M, Ozuah PO. Perceptions and attitudes of adolescents with asthma. J Asthma 2003;40:207-11.
22. Guevara JP, Wolf FM, Grum CM, Clark NM. Effects of educational interventions for self-management of asthma in children and adolescents: systematic review and meta-analysis. BMJ 2003;326:1308-13.
23. Shah S, Peat JK, Mazurski EJ, Wang H, Sindhusake D, Bruce C, et al. Effect of peer led programme for asthma education in adolescents: cluster randomised controlled trial. BMJ 2001;322:583-5.
24. 2-agonists. Eur Respir J 1998; 12(Suppl.): 156-7.
25. McCarthy TP, Rice L, Blair CA. Improved compliance with asthma therapy in children treated with salmeterol/fluticasone propionate combination (SFC) compared with concurrent salmeterol (S) plus inhaled corticosteroid (ICS) or ICS alone. Am J Respir Crit Care Med 2003;167(7): A660.
26. Busse WW, Chervinsky P, Condemi J, Lumry WR, Petry TL, Rennard S, et al. Budesonide delivered by Turbuhaler is effective in a dose-dependent fashion when used in the treatment of adult patients with chronic asthma. J Allergy Clin Immunol 1998;101(4 Pt 1):457-63.
27. Shapiro G, Bronsky EA, LaForce CF, Mendelson L, Pearlman D, Schwartz RH, et al. Dose-related efficacy of budesonide administered via a dry powder inhaler in the treatment of children with moderate to severe persistent asthma. J Pediatr 1998;132(6): 976-82.
28. Kemp J, Wanderer AA, Ramsdell J, Southern DL, Weiss S, Aaronson D, et al. Rapid onset of control with budesonide Turbuhaler in patients with mild-to-moderate asthma. Ann Allergy Asthma Immunol 1999;82(5):463-71.
29. Tsai YG, Lee MY, Yang KD, Chu DM, Yuh YS, Hung CH. A single dose of nebulized budesonide decreases exhaled nitric oxide in children with acute asthma. J Paediatr 2001; 139(3):433-7.
30. Volovitz B, Bentur L, Finkelstein Y, Mansour Y, Shalitin S, Nussinovitch M, et al. Effectiveness and safety of inhaled corticosteroids in controlling acute asthma attacks in children who were treated in the emergency department: a controlled comparative study with oral prednisolone. Allergy Clin Immunol 1998;102(4 Pt 1):605-9.
31. Jónasson G, Carlsen K-H, Jónasson C, Mowinckel P. Low-dose inhaled budesonide once or twice daily for 27 months in children with mild asthma. Allergy 2000;55(8):740-8.
32. Childhood Asthma Management Program Research Group. Long-term effects of budesonide or nedocromil in children with asthma. N Engl J Med 2000;343(15):1054-63.
33. Agertoft L, Pedersen S. Effect of long-term treatment with inhaled budesonide on adult height in children with asthma. N Engl J Med 2000;343(15):1064-9.
34. Bartow RA, Brogden RN. Formoterol. An update of its pharmacological properties and therapeutic efficacy in the management of asthma. Drugs 1998;55(4):303-22.
35. Ringdal N, Derom E, Wåhlin-Boll E, Pauwels R. Onset and duration of action of single doses of formoterol inhaled via Turbuhaler®. Respir Med 1998;92(8):1017-21.
36. Palmqvist M, Persson G, Lazer L, Rosenborg J, Larsson P, Lotvall J. Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency. Eur Respir J 1997;10(11): 2484-9.
37. Pohunek P, Matulka M, Rybníček O, Kopřiva F, Honomichlová H, Svobodová T. Dose-related efficacy and safety of formoterol (Oxis®) Turbuhaler®) compared with salmeterol Diskhaler® in children with asthma. Pediatric Allergy Immunol 2004; 15: 32-9.
38. Grönneröd TA, von Berg A, Schwabe, G, Soliman S. Formoterol via Turbuhaler® gave better protection than terbutaline against repeated exercise challenge for up to 12 hours in children and adolescents. Respir Med 2000; 94 (7): 661-7.
39. Zetterström O, Buhl R, Mellem H, Perpiná M, Hedman J, O'Neill S, et al. Improved asthma control with budesonide/formoterol in a single inhaler, compared with budesonide alone. Eur Respir J 2001; 18(2):262-8.
40. Buhl R, Creemers JP, Vondra V, Martelli NA, Naya IP, Ekstrom T. Once-daily budesonide/formoterol in a single inhaler in adults with moderate persistent asthma. Respir Med 2003; 97(4):323-30.
41. Lalloo UG, Malolepszy J, Kozma D, Krofta K, Ankerst J, Johansen B, et al. Symbicort® (budesonide and formoterol in a single inhaler) improves asthma control compared with increasing the dose of corticosteroids in adults with mild-to-moderate asthma. Chest 2003;123(5): 1480-7.
42. Bateman ED, Bantje TA, Joao Gomes M, Toumbis M, Huber R, Eliraz A. Symbicort® (budesonide and formoterol in a single inhaler) is more effective than fluticasone in the treatment of adults with asthma. Am J Respir Med 2003; 2(3):275-81.
43. Ankerst J, Persson G, Weibull E. Tolerability of a high dose of budesonide/formoterol in a single inhaler in patients with asthma. Pulm Pharmacol Ther 2003; 16:147-51.
44. Palmqvist M, Arvidsson P, Beckman O, Peterson S, Lötvall J. Onset of bronchodilation of budesonide/formoterol vs salmeterol/fluticasone in single inhalers. Pulm Pharmacol Ther 2001; 14(1):29-34.
45. Balanag VN, Yunus F, Yang P-C, Jorup C. Budesonide/formoterol in a single inhaler is as effective and well tolerated as salbutamol in relieving acute asthma in adults and adolescents. Eur Respir J 2003;22 (Suppl. 45):445s.
46. van der Woude HJ, Boorsma M, Bergqvist PBF, Winter TH, Aalbers R. Budesonide/formoterol in a single inhaler rapidly relieves methacholine-induced moderate-to-severe broncho-constriction. Pulm Pharmacol Ther 2004; 17:89-95.
47. Foresi A, Morelli MC, Catena E. Low-dose budesonide with the addition of an increased dose during exacerbations is effective in long-term asthma control. Chest 2000;117(2): 440-6.
48. Ställberg B, Olsson P, Jorgensen LA, Lindarck N, Ekstrom T. Budesonide/formoterol adjustable maintenance dosing reduces asthma exacerbations versus fixed dosing. Int J Clin Pract 2003;57:656-61.
49. FitzGerald M, Boulet LP, McIvor A, Becker A, Sears MR, Ernst P, Smiljanic-Georgijev N, Lee J. Adjustable maintenance dosing with budesonide/formoterol reduces asthma exacerbations compared with fixed dosing - a 5-month multicentre Canadian study. Can Respir J. 2003; 10:427-34.
50. Tal A, Simon G, Vermeulen JH, Petru V, Cobos N, Everard ML, et al. Budesonide/formoterol in a single inhaler versus inhaled corticosteroids alone in the treatment of asthma. Pediatr Pulmonol 2002;34(5):342-50.
51. Tal A, Simon G, Vermeulen JH, Petrů, Cobos N, Everard ML, et al. Rapid and sustained improvements in lung function and symptom control with budesonide/formoterol in adolescent asthma. Eur Respir J 2001; 18 (Suppl. 33): 494s.
52. Aubier M, Pieters WR, Schlösser NJJ, Steinmetzm K-O. Salmeterol/fluticasone propionate (50/500 μg) in combination in a Diskus inhaler (Seretide®) is effective and safe in the treatment of steroid-dependent asthma. Respir Med 1999;93(12):876-84.
53. Lindén A, Bergendal A, Ullman A, Skoogh BE, Lofdahl C-G. Salmeterol, formoterol, and salbutamol in the isolated guinea pig trachea: differences in maximum relaxant effect and potency but not in functional antagonism. Thorax 1993;48(5):547-53.
54. Agertoft L, Friberg M, Pedersen S. One year treatment of mild asthma in children with budesonide or nedocromil. J Allergy Clin Immunol 2000;105 (1 Pt2):S260-S261.
55. Leff JA, Busse WW, Pearlman D, Bronsky EA, Kemp J, Hendeles L, et al. Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced broncho-constriction. N Engl J Med 1998; 339(3):147-52.
56. Reiss TF, Chervinsky P, Dockhorn RJ, Shingo S, Seidenberg B, Edwards TB. Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma. Arch Intern Med 1998;158:1213-20.
57. Knorr B, Matz J, Bernstein JA, Nguyen H, Seidenberg BC, Reiss TF, et al. Montelukast for chronic asthma in 6- to 14-year-old children. JAMA 1998;279(15):1181-6.
58. Ducharme FM, Hicks GC. Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma. Cochrane Database Syst Rev 2000;(3):CD002314.
59. Ducharme FM. Inhaled glucocorticoids versus leukotriene receptor antagonists as single agent treatment: systematic review of current evidence. BMJ 2003;326:621-5.
60. Vaquerizo MJ, Casan P, Castillo J, Perpina M, Sanchis J, Sobradillo V, et al. Effect of montelukast added to inhaled budesonide on control of mild to moderate asthma. Thorax 2003; 58:204-10.
61. Price DB, Hernandez D, Magyar P, Fiterman J, Beeh KM, James IG, et al. Randomised controlled trial of montelukast plus inhaled budesonide versus double dose inhaled budesonide in adult patients with asthma. Thorax 2003;58:211-6.
62. Simons FE, Villa JR, Lee BW, Teper AM, Lyttle B, Aristizabal G, et al. Montelukast added to budesonide in children with persistent asthma: a randomised, double-blind, crossover study. J Pediatr 2001; 138:694-8.
63. Nelson HS, Busse WW, Kerwin E, Church N, Emmett A, Rickard K, et al. Fluticasone propionate/salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast. J Allergy Clin Unmunol 2000; 106(6):1088-95.
64. Ducharme F, Hicks G, Kakuma R. Addition of anti-leukotriene agents to inhaled corticosteroids for chronic asthma (Cochrane Review). Cochrane Database Syst Rev. 2002;(1): CD003133.
65. Currie GP, Lee DK, Haggart K, Bates CE, Lipworth BJ. Effects of triple therapy with fluticasone/salmeterol combination and montelukast on surrogate inflammatory outcomes. Am J Respir Crit Care Med 2003;167(7): A891.
66. Evans DJ, Taylor DA, Zetterstrom O, Chung KF, O'Connor BJ, Barnes PJ. A comparison of low-dose inhaled budesonide plus theophylline and high-dose inhaled budesonide for moderate asthma. N Engl J Med 1997;337(2): 1412-8.
67. Wilson AJ, Gibson PG, Coughlan J. Long-acting beta-agonists versus theophylline for maintenance treatment of asthma. Cochrane Database Syst Rev 2000;(2):CD001281.